BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2603BiotechnologyAI medical concept stocks
$4.78 +$0.66 (+16.02%)
Pre-market · Oct 6, 4:10 am ET · After hours $4.76 -0.42%
Open$4.16
Prev close$4.12
Day range$4.06 – $4.94
Volume67.28M
Market cap$2.56B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-4.8x
CheapRich

Around its usual level · 49th percentile, 5-year average -5.3x

Price / book2.8x
CheapRich

Around its usual level · 42nd percentile, 5-year average 3.4x

#3530 of 5315 stocks by PB (1 = cheapest)

Price / sales46.6x
CheapRich

Around its usual level · 57th percentile, 5-year average 68.5x

#4825 of 5147 stocks by PS (1 = cheapest)

P/E over five years

-16x-11x-6x-1xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$5.73
Price vs. fair value-16.6%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.80 – 3.41 42% (cheaper than usual) #3530 of 5315 (1 = cheapest)
PE -4.78 -5.61 -5.34 49% (cheaper than usual) –
PS 46.65 46.83 68.48 57% (pricier than usual) #4825 of 5147 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★
Fair value estimate$5.73
Economic moatNone
UncertaintyVery High

Discussion

No comments yet — be the first to weigh in on RXRX.

Leave a comment

Scroll to Top